NZ600010A - Novel crystalline forms of bosentan, processes for their preparation and uses thereof - Google Patents

Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Info

Publication number
NZ600010A
NZ600010A NZ600010A NZ60001008A NZ600010A NZ 600010 A NZ600010 A NZ 600010A NZ 600010 A NZ600010 A NZ 600010A NZ 60001008 A NZ60001008 A NZ 60001008A NZ 600010 A NZ600010 A NZ 600010A
Authority
NZ
New Zealand
Prior art keywords
bosentan
processes
preparation
crystalline forms
novel crystalline
Prior art date
Application number
NZ600010A
Other languages
English (en)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Prakash Bansode
Dattatraya Shinde
Sunanda Phadtare
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of NZ600010A publication Critical patent/NZ600010A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ600010A 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof NZ600010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2108MU2007 2007-10-24
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Publications (1)

Publication Number Publication Date
NZ600010A true NZ600010A (en) 2013-11-29

Family

ID=40262729

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Country Status (8)

Country Link
US (1) US8530488B2 (enExample)
EP (1) EP2222649A2 (enExample)
JP (1) JP2011500780A (enExample)
CN (1) CN101939303B (enExample)
AU (1) AU2008315757A1 (enExample)
CA (1) CA2703230A1 (enExample)
NZ (2) NZ600010A (enExample)
WO (1) WO2009053748A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288401B2 (en) * 2007-05-08 2012-10-16 Generics [Uk] Limited Polymorphic forms
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・（ユーケー）・リミテッド 新規結晶形
NZ586900A (en) 2008-01-01 2012-10-26 Cipla Ltd Anhydrous polymorphic form b of bosentan and uses thereof
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
US8785461B2 (en) 2008-02-08 2014-07-22 Generics [Uk] Limited Process for preparing bosentan
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
EP2350028A1 (en) 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CZ20021642A3 (cs) 1999-11-17 2003-05-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy atorvastatinu vápenatého
US6610718B2 (en) 1999-12-16 2003-08-26 Teva Pharmaceutical Industries Ltd. Processes for making- and a new crystalline form of- leflunomide
DE60025803T2 (de) * 2000-01-25 2006-11-02 F. Hoffmann-La Roche Ag Herstellung von sulfonamiden
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
WO2004076443A1 (en) 2003-02-25 2004-09-10 Hetero Drugs Limited Amorphous form of losartan potassium
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
US7772399B2 (en) 2003-04-02 2010-08-10 Hetero Drugs Limited Process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
WO2008122020A1 (en) 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
US8288401B2 (en) * 2007-05-08 2012-10-16 Generics [Uk] Limited Polymorphic forms
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) * 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・（ユーケー）・リミテッド 新規結晶形
EP2072503B1 (en) 2007-12-18 2011-10-26 Dipharma Francis S.r.l. Process for the preparation of bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
US8785461B2 (en) 2008-02-08 2014-07-22 Generics [Uk] Limited Process for preparing bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
EP2294056A1 (en) 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
EP2350028A1 (en) 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
AU2008315757A1 (en) 2009-04-30
JP2011500780A (ja) 2011-01-06
WO2009053748A2 (en) 2009-04-30
US8530488B2 (en) 2013-09-10
EP2222649A2 (en) 2010-09-01
WO2009053748A3 (en) 2009-06-18
CN101939303B (zh) 2014-06-11
NZ585438A (en) 2012-09-28
US20100331352A1 (en) 2010-12-30
CA2703230A1 (en) 2009-04-30
CN101939303A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
NZ585438A (en) Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
Ludovici et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues
WO2006034473A3 (en) Novel pyrimidine compounds, process for their preparation and compositions containing them
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
CN101914065A (zh) 有助于治疗由crth2介导的疾病的嘧啶衍生物
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
PE20070407A1 (es) Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina
WO2007027238A3 (en) Jak kinase inhibitors and their uses
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
HRP20050780A2 (hr) Novitetni kvinolin, tetrahidrokvinazolin i derivati pirimidina, kao i metode tretmana koji se povezani s njihovim korištenjem
TW200602058A (en) Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
EP4275754A3 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
WO2009080721A3 (en) 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists
ATE133944T1 (de) Substituierte aminopyrimidine als angiotensin ii antagonisten
TN2010000070A1 (en) Fused bicyclic pyrimidines
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
MX2022013804A (es) Polimorfos de moduladores de los receptores de pirimidin-ciclohexil-glucocorticoides.
MX2007015427A (es) Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres.
WO2006135839A3 (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
EP2769721A3 (en) Process for the preparation of substituted pyrimidine derivatives
WO2007041076A3 (en) 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
WO2009024323A3 (en) Process for preparing pyrimidine derivatives
WO2009128091A3 (en) Crystalline form of(7-[4-(4-fluorophenyl)-6-isopropyl-2-(n- methyl-n-methylsulfonylamino)pyrimidin-5-yl]-(3r,5s)- dihydroxy-(e)-6-heptenoic acid intermediate, process for preparing the same and use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed